Accessibility Menu
Cnbx Pharmaceuticals logo

Cnbx Pharmaceuticals(OTC) CNBX

Market Cap$160.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year-80%
1 Month-31%
$0.00
+0.00%
+0.00Today
Cnbx Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-03
Cnbx Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-27
1 month-31.03%USD 0.002026-07-02
3 month-50%USD 0.002026-05-05
Year to date-75%USD 0.002025-12-31
1 year-80%USD 0.002025-08-01
3 year-99.29%USD 0.012023-08-04
5 year-100%USD 20.882021-08-04
Since inception-100%USD 21.002011-05-20

Cnbx Pharmaceuticals Financials at a Glance

Market Cap

$160.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$462.09K

EPS (TTM)

-$0.00

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$0.00

Volume

115,038

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Apr 13, 2026

CNBX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cnbx Pharmaceuticals

CNBX develops cannabinoid-based medicines for cancer patients. Its main products aim to ease cancer symptoms and target tumor growth. These treatments are designed for people with cancer and related conditions.

Lab Bench to Bedside: What CNBX Sells

  • RCC-33 (Lead Drug): Oral capsule for colorectal cancer; not yet generating revenue.
  • Cannabics SR: Sustained-release capsule for cancer-related weight loss; no product sales to date.
  • Pipeline Drugs: PLP-33 (colorectal polyps), BRST-33 (breast cancer), MLN-33 (melanoma), PRST-33 (prostate cancer); all in early development.
  • Laboratory Services: Provided all reported revenue (100%) in 2024; no product sales yet.
  • Cannabics CDx: Drug sensitivity test for cancer patients; not actively developed as of 2024.

Growth Spurts and Growing Pains

  • Changed name from Cannabics Pharmaceuticals to CNBX in May 2022.
  • Focused on advancing RCC-33 and Cannabics SR to clinical trials by 2026.
  • Plans to outsource manufacturing to suppliers like Purisys for clinical trial materials.
  • Research and development has been based in Israel since 2014.
  • Plans to commercialize through licensing and partnerships, not direct sales.

What Makes CNBX Stand Out (Besides the Name)

CNBX specializes in cannabinoid-based cancer therapies, a niche within biotechnology. The company outsources manufacturing and leverages Israeli research labs for development. Its business model centers on intellectual property and early-stage clinical progress, not direct product sales.

Five Things You Need to Know

  • Revenue was $130,074 in 2024, down 68.3% from 2023.
  • Net loss was $695,198 in 2024, improved from $3.7 million in 2023.
  • Cash position was $26,416 as of August 31, 2024.
  • All 2024 revenue came from laboratory services, not drug sales.
  • Auditors raised doubt about CNBX’s ability to continue as a going concern.

Bottom Line

CNBX has shifted from laboratory services to developing cannabinoid-based cancer drugs. The company faces financial challenges but continues to focus on early-stage research and licensing opportunities.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1

CEO

Eyal Barad, MBA

Website

www.cnbxpharma.com

Headquarters

Bethesda, MD 20814, US

CNBX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

18.01%

Return on Capital

N/A

Return on Assets

-3611.50%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$160.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.61B

Volume

115.04K

Avg. Volume

22.12M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$429.46K

EBITDA

-$431.55K

Operating Cash Flow

-$154.17K

Capital Expenditure

-$3.00

Free Cash Flow

-$154.17K

Cash & ST Invst.

$9.49K

Total Debt

$120.00K

Cnbx Pharmaceuticals Performance Analysis

Cnbx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31USD 29,958N/A
20232023-08-31USD 410,1651269.1%
20242024-08-31USD 130,074-68.3%
20252025-08-31USD 0N/A
Cnbx Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31N/A
Q12025-11-30N/A
Q22026-02-28N/A
Q32026-05-31N/A
Cnbx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31USD -3.0510.0%
20232023-08-31USD -0.42-86.2%
20242024-08-31USD -0.02-94.5%
20252025-08-31USD -0.00-84.8%
Cnbx Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31185.7%
Q12025-11-30-116.7%
Q22026-02-28100.0%
Q32026-05-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$160.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$160.60K

N/A

Employees

1

N/A

Net Income

-$154.17K

-158.1%

EBITDA

-$162.76K

-303.1%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$9.49K

-30.5%

Total Debt

$120.00K

-91.0%

Accounts Receivable

$3.31K

-33.4%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$120.00K

-91.0%

Return on Assets

-36.11%

N/A

Return on Invested Capital

16.15%

N/A

Free Cash Flow

-$47.67K

+8.4%

Operating Cash Flow

-$47.67K

+8.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TNPHTian'an Pharmaceutical Co., Ltd.
$0.01+0.00%
AFFYAffymax, Inc.
$0.00+0.00%
ENDVEndonovo Therapeutics, Inc.
$0.00+0.00%
MCRTMicroart Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About CNBX

What is the current price of Cnbx Pharmaceuticals?

Cnbx Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Cnbx Pharmaceuticals?

Over the past 52 weeks, Cnbx Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does Cnbx Pharmaceuticals have?

As of the most recent reporting period, Cnbx Pharmaceuticals reported total debt of $1.17M.

How much cash does Cnbx Pharmaceuticals have on hand?

Cnbx Pharmaceuticals reported $9.49K in cash and cash equivalents in its most recent financial results.

What is Cnbx Pharmaceuticals’s dividend yield?

Cnbx Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services